60 Degrees Pharmaceuticals filings document a specialty pharmaceutical issuer with Nasdaq-listed common stock and warrants, emerging-growth-company status and a business focused on medicines for vector-borne disease. Its recent Form 8-K disclosures record material events involving the company’s at-the-market equity offering program, related legal opinions, beneficial-ownership corrections, investor-presentation materials, and clinical development and regulatory strategy updates.
The filing record also covers capital-structure and governance matters, including a one-for-four reverse stock split approved through amendments to the certificate of incorporation, annual meeting voting results and Nasdaq listing-compliance notices. These disclosures frame the company’s formal reporting around ARAKODA, tafenoquine development, equity financing mechanics, security-holder votes and exchange-related requirements.
60 Degrees Pharmaceuticals, Inc. reported a net loss attributable to common stockholders of $2.21 million for the quarter ended March 31, 2026, compared with $2.00 million a year earlier. Net product revenue was $162,092, essentially flat versus $163,552 in 2025, while prior-year research revenue of $92,731 did not recur.
Operating expenses rose slightly to $2.17 million, driven mainly by general and administrative costs of $1.89 million, with research and development at $281,464. Cash used in operating activities was $2.74 million, but the company boosted liquidity through at-the-market equity sales, ending the quarter with cash and cash equivalents of $3.34 million.
Management discloses an accumulated deficit of $49.98 million and explicitly states that recurring losses, limited cash runway and funding needs raise substantial doubt about the company’s ability to continue as a going concern for one year from the issuance of these financial statements.
60 Degrees Pharmaceuticals reports beneficial ownership disclosure showing 263,158 shares of Common Stock (approximately 9.1%) attributable collectively to Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC as of the close of business on March 31, 2026.
The filing states the 263,158 shares reflect 131,579 shares issuable upon exercise of each of two warrants held by Intracoastal and is calculated using 2,636,788 shares outstanding as of March 30, 2026. The filing also explains multiple additional warrants contain blocker provisions that limit exercise to avoid exceeding 4.99% ownership; without those blockers, beneficial ownership would be 307,543 shares.
60 Degrees Pharmaceuticals, Inc. files its annual report describing a specialty infectious disease business built around tafenoquine and celgosivir. The company markets Arakoda for malaria prevention and is developing tafenoquine for tick‑borne babesiosis, veterinary babesiosis and respiratory fungal and viral infections.
It strengthened its balance sheet through multiple 2024–2026 equity raises, including at‑the‑market programs and several registered direct and private warrant offerings that collectively brought in several million dollars of net proceeds. The report also details an extensive patent and trademark portfolio and ongoing clinical trials intended to support potential label expansions and new products.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to correct an error in previously disclosed share ownership for a company affiliate. A March 13, 2026 prospectus supplement had shown the affiliate as beneficially owning 21,490 shares; the correct figure is 23,367 shares. The error traces back to an incorrect total in a Form 4 dated September 15, 2025 that was carried into a December 16, 2025 Form 4 and then into the prospectus disclosure. After giving effect to the 1-for-4 reverse stock split, the corrected total number of shares beneficially owned is 16,781 instead of 15,905. The company states that no other information in the prospectus supplement is affected.
60 Degrees Pharmaceuticals amended its ATM prospectus to increase the offering capacity to $565,000. This figure gives effect to 325,200 shares previously sold for aggregate gross proceeds of $980,510.52 under the Sales Agreement with H.C. Wainwright & Co.
The supplement states shares outstanding were 2,472,949 and public float was $12,747,587 based on 2,451,459 shares held by non-affiliates and a closing price of $5.20 per share on January 28, 2026. The company effected a one-for-four reverse stock split on January 20, 2026. The last reported sale price on Nasdaq was $2.91 on March 12, 2026.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to report that it obtained and filed an updated legal opinion from Sichenzia Ross Ference Carmel LLP covering shares of common stock issued and sold under its at-the-market equity offering program with HC Wainwright & Co., LLC.
The opinion, filed as Exhibit 5.1 with an associated consent in Exhibit 23.1, confirms the validity of shares that may be sold under the program and addresses related legal matters. The company states that this updated opinion does not change the existing terms of the at-the-market program.
60 Degrees Pharmaceuticals, Inc. filed a Form 8-K to note that it obtained and filed an updated legal opinion from its counsel covering shares of common stock issued and sold under its existing at-the-market equity offering program with HC Wainwright & Co., LLC.
The company states that this opinion does not change the terms of the at-the-market program. Instead, it confirms the validity of shares that may be sold under the program and addresses certain legal matters related to those sales under applicable law.
60 Degrees Pharmaceuticals, Inc. amends its at-the-market program to permit the offer and sale of up to $981,000 of common stock pursuant to the Sales Agreement with H.C. Wainwright & Co., LLC, March 11, 2026.
The $981,000 capacity reflects and includes 566,067 shares previously sold for aggregate gross proceeds of $1,307,508.15 under the Sales Agreement. The company reports a public float of $11,056,547 based on 2,147,749 outstanding shares, of which 2,126,259 were held by non-affiliates as of January 28, 2026. The company effected a one-for-four reverse stock split on January 20, 2026.
60 Degrees Pharmaceuticals amends its at-the-market program to register up to $1,308,000 of common stock pursuant to its September 5, 2025 Sales Agreement with H.C. Wainwright & Co., LLC.
The prospectus supplement updates the aggregate offering capacity to $1,308,000, excluding 555,593 shares previously sold for aggregate gross proceeds of $1,396,091. It states a public float of approximately $8,112,998 based on 1,581,682 shares outstanding as of January 28, 2026 and notes a one-for-four reverse stock split effective January 20, 2026. The filing cites the Form S-3 limitation that sales will not exceed one-third of public float in a 12-month period.
60 Degrees Pharmaceuticals, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2). Nasdaq’s Listing Qualifications Staff confirmed the company now meets all Nasdaq Capital Market listing standards.
The company had previously received a delisting notice after its stock traded below $1.00 for 30 consecutive business days and paid a $20,000 hearing fee to appeal. With compliance restored, the February 19, 2026 Nasdaq Hearings Panel session has been cancelled, the delisting matter is closed, and the company’s common stock and warrants will continue to trade on The Nasdaq Capital Market.